Price achieved by oncology vs. non-oncology rare disease products by ASMR
CRA Life Sciences continues its series on leveraging RADAR, an orphan drug data repository. With rare oncology diseases in the spotlight at ASCO this season,...
Strategy in rare disease requires specialist expertise and understanding. CRA understands the unique challenges that rare disease companies face, and we implement a distinctive approach to help drive their success.
Follow us on LinkedIn: CRA on Rare Disease
We are rare disease specialists.
CRA’s experience stems from hundreds of rare disease engagements across many therapeutic areas.
- 50+Rare disease areas covered
- 500+Rare disease engagements since 2019
Our rare disease offerings span across the product lifecycle.
- Early developmentDiscover
- Pipeline opportunity assessment
- Diagnostics & screening
- Early Pricing Marketing Access (PMA)
- Licensing / commercially reasonable efforts disputes
- Late developmentDevelop
- Market access & evidence generation strategy
- Payer value proposition
- Patient finding
- Landscape assessment & policy shaping
- LaunchDeliver
- Launch pricing strategy
- Payer negotiation
- Launch excellence
- Stakeholder engagement
- Competitive simulations
- Uptake and diffusion
- Life cycle & LOEDefend
- Indication & geographic expansion
- Competitor response strategies
- Price/access/uptake benchmarking and assessments
- LOE strategies
Engagements
- 01Strategic and statistical consulting involving rare disease pharmaceuticalsThe CRA expert reviewed data from a variety of existing studies and analyzed limitations and opportunities regarding the use of such data. Client relied upon...View engagement
- 02Developed dynamic GTN model to guide pricing and contracting strategy for a rare disease assetA leading pharmaceutical company engaged CRA’s Life Sciences consultants for support in developing a pricing and contracting strategy for a rare disease assetView engagement
- 03Evaluating the potential impact of cross-border healthcare for gene therapiesCRA's Rare Disease team evaluated the dynamics of cross-border healthcare using secondary research to explore current precedence and/or previous product...View engagement
Contact a Rare Disease expert.
See all Rare Disease expertsRecent and Upcoming Events
ISPOR Europe 2024
CRA had four posters accepted at the conference. Kirsten Axelsen and Charlotte Poon present their poster titled “Assessing the economic burden of rare disease...
World Orphan Drug Congress EU 2024
CRA is a proud sponsor of the conference. Come visit us at booth #41! Bhavesh Patel and Owen Male present the session titled “Maximizing Value & Positioning in...